Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
US8926994B2 · kind B2 · utility
19Cited by
0References
36Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 7, 2012 |
| Grant date | Jan 6, 2015 |
| Priority date | — |
| Expiry date | Dec 7, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/57
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are mesoporous silicon multi-stage vehicles that comprise liposomal-based second-stage particles, as well as pharmaceutical compositions and formulations including such vectors for use in a variety of diagnostic and therapeutic indications. In particular embodiments, MSV comprising ligand decorated second-stage particles are provided for therapeutic methods including, for example, treatment of mammalian cancers, including those of the human breast.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.